Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with or without platinum-based chemotherapy in first-line metastatic urothelial carcinoma
jRCT2080223468Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in transitional cell carcinoma (TCC) and urothelial carcinoma (UC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Feb 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on jRCT2080223468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223468.